Silence Therapeutics (SLN) Interest Coverage Ratio (2024 - 2025)
Silence Therapeutics (SLN) reported Interest Coverage Ratio of 77.88 for Q4 2025, down 109860.74% on a YoY basis from N/an in Q4 2024, and down 109860.74% sequentially from 0.07 in Q4 2024.
Silence Therapeutics (SLN) Interest Coverage Ratio (2024 - 2025) Analysis & Trends
Silence Therapeutics (SLN) has 2 years of Interest Coverage Ratio data on file, last reported at 77.88 in Q4 2025.
- For the quarter ending Q4 2025, Interest Coverage Ratio fell 109860.74% year-over-year to 77.88; the trailing twelve-month figure through Dec 2025 stood at 569.23 (down 55140.19% YoY), and the FY2025 full-year result was 1.13, down 9.91% from the prior year.
- Interest Coverage Ratio retreated to 77.88 in Q4 2025, from 0.07 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 0.07 in Q4 2024 to a low of 77.88 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Silence Therapeutics | 1.62 Bn | 1.49 Bn | 411,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -77.88 |
| Dec 31, 2024 | -0.07 |